Morinda officinalis extract exhibits protective effects against atopic dermatitis by regulating the MALAT1 / miR ‐590‐5p/ CCR7 axis
Journal of Cosmetic Dermatology · 2023
DOI: 10.1111/jocd.15610 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, 2023. Verfasst von Huan-Huan Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Morinda, RNA, Long Noncoding, MicroRNAs. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Key R&D and Promotion Project of Henan Province (tackling key problems in science and technology).
Abstract (Originalsprache)
Background
Atopic dermatitis (AD) is a chronic inflammatory skin disease with a genetic predisposition, and the traditional Chinese medicine Morinda officinalis and its roots are characterized with anti‐inflammatory effects and have been used for the treatment of various disease. However, it is still largely unknown whether Morinda officinalis extract (MOE) can be used for the treatment of AD.
Objectives
In our study we aimed to determine whether MOE could ameliorate 2,4‐dinitrochlorobenzene (DNCB)‐induced AD and elucidate molecular mechanisms.
Methods
We established an AD mouse model by using DNCB. Skin pathological analysis and ELISA assay were used to detect the effect of MOE on the inflammation of AD model mouse skin and the expression changes of inflammatory factors, and further functional verification was performed in TNF‐α/IFN‐γ‐induced HaCaT cells.
Results
Our in vivo experiments confirmed that MOE remarkably reduced DNCB‐induced AD lesions and symptoms, such as epidermal and dermal thickness and mast cell infiltration and inflammatory cytokines secretion in the mice models. In addition, the underlying mechanisms by which MOE ameliorated AD had been uncovered, and we verified that MOE inhibited MALAT1 expression in AD, resulting in attenuated expression of C‐C chemokine receptor type 7 (CCR7) regulated by MALAT1‐sponge miR‐590‐5p in a competing endogenous RNA (ceRNA) mechanisms‐dependent manner, thereby inhibiting TNF‐α/IFN‐γ‐induced cellular proliferation and inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, China.
ORCID-Profile: Huan-Huan Yu, Wei Zhao, Bu-Xin Zhang, Ying Wang, Jie Li, Yu-Fu Fang
Förderung
- The Key R&D and Promotion Project of Henan Province (tackling key problems in science and technology)
Zitieren
APA
Yu, H. H., Zhao, W., Zhang, B. X., Wang, Y., Li, J., & Fang, Y. F. (2023). Morinda officinalis extract exhibits protective effects against atopic dermatitis by regulating the MALAT1 / miR ‐590‐5p/ CCR7 axis. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.15610
Vancouver
Yu HH, Zhao W, Zhang BX, Wang Y, Li J, Fang YF. Morinda officinalis extract exhibits protective effects against atopic dermatitis by regulating the MALAT1 / miR ‐590‐5p/ CCR7 axis. Journal of Cosmetic Dermatology. 2023. doi:10.1111/jocd.15610
BibTeX
@article{Yu2023,
author = {Yu, Huan-Huan and Zhao, Wei and Zhang, Bu-Xin and Wang, Ying and Li, Jie and Fang, Yu-Fu},
title = {Morinda officinalis extract exhibits protective effects against atopic dermatitis by regulating the MALAT1 / miR ‐590‐5p/ CCR7 axis},
journal = {Journal of Cosmetic Dermatology},
year = {2023},
doi = {10.1111/jocd.15610}
}
EUVIMED